Search Results 871-880 of 19305 for hemoglobin

  1. Neurology - Clinical trials

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

  2. To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis - Mayo Clinic

    Unwillingness to receive RBC transfusions to treat low hemoglobin levels. ... Receipt of any live vaccine within 30 days of the first dose of study drug.

  3. Bendamustine Hydrochloride and Rituximab with or without Bortezomib Followed by Rituximab with or without Lenalidomide in Treating Patients with High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma - Mayo Clinic

    Hemoglobin level < 12 g/dL; > 4 nodal areas; Serum LDH level above normal. At least 1 objective measurable disease parameter. Baseline measurements and ...

  4. Sleep Restriction and Parental History of Hypertension - Mayo Clinic

    * Exclusionary for blood draws: hemoglobin \<11.6 g/dL in women / \<13.2 g/dL in men; participants with measured hemoglobin levels below these thresholds ...

  5. Clinical trials - Oncology (Medical)

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

  6. Oncology (Medical) - Clinical trials

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

  7. Imatinib (oral route) - Side effects & dosage - Mayo Clinic

    Aggressive systemic mastocytosis (ASM); Chronic eosinophilic leukemia (CEL); Dermatofibrosarcoma protuberans (DFSP); Gastrointestinal stromal tumors (GIST) ...

  8. What the New Screening Guidelines for Children's Checkups Mean - Mayo Clinic News Network

    A risk assessment has been added at 15 and 30 months for hematocrit or hemoglobin screening to help detect anemia, an iron deficiency. An HIV screen was ...

  9. Clinical trials - Oncology (Medical)

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

  10. An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies - Mayo Clinic

    Participation eligibility · Hemoglobin ≤9.0 g/dL · Platelet count ≤75 × 109/L · ANC ≤ 1.0 × 109/L · Total bilirubin ≥ 1.5 × ULN · AST or ALT ≥5 × ULN · ALP ≥ ...